

Carefully Time Antiretrovirals During Pregnancy

BY ROBERT FINN
San Francisco Bureau

SAN FRANCISCO — The optimal time to initiate antiretroviral therapy during pregnancy depends on a balance of factors, Dr. Deborah Cohan said at a meeting on HIV management sponsored by the University of California, San Francisco.

The primary goal is viral suppression by the third trimester to minimize the chances of HIV transmission to the fetus. At least

one study shows that the median time to viral suppression is about 50 days in pregnant women, although 10% fail to achieve total suppression within 6.5 months.

“In the United States we tend to start antiretrovirals between 12 and 14 weeks or beyond,” said Dr. Cohan of the University of California, San Francisco. “[Many women] feel pretty bad in the first trimester, and the last thing we want is for them to ... attribute their nausea and vomiting to the antiretrovirals.”

Fortunately the weight of the evidence is that transmission does not occur in the first trimester, so antiretroviral therapy may not be crucial during that time.

There are situations in which antiretroviral therapy would be appropriate during the first trimester. For example, if the woman is continuing her preconception regimen, and the regimen includes only nonteratogenic medications that are well tolerated, it need not be discontinued.

First-trimester antiretrovirals also are

indicated in patients who need them immediately for their own health.

For women who fail to tolerate their preconception regimen during the first trimester despite the use of antiemetics, the advice is to discontinue all medications at once. The one exception is if the patient is on a regimen containing nonnucleoside reverse transcription inhibitors. In that case, discontinuation should be staggered.

The principles of determining a proper antiretroviral regimen are similar in pregnant and nonpregnant women, except for one major consideration: Is this for her own health, and is it going to be a long-term regimen, or is it strictly chemoprophylaxis to prevent transmission?

If it's chemoprophylaxis, less potent regimens may be acceptable. These could include triple nucleoside reverse trans-

criptase inhibitors. “Triple nukes really have fallen out of favor in terms of chronic use in adults,” Dr. Cohan said. “In this setting it may be appropriate. If someone comes to you with a CD4 count of 600 [cells/mm³]

and a baseline viral load of 3,000 [copies/mL], and she's going to be on antiretrovirals for 5 months and she really would like to reduce her pill burden, Trizivir [abacavir, lamivudine, and zidovudine] may be a good option.”

Nelfinavir, a less potent protease inhibitor that has fallen out of favor, also is an option. It tends to be quite well tolerated in pregnancy, and in fact can counter the constipation that pregnant women frequently experience.

Another question concerns whether antiretroviral therapy is needed in pregnant women with viral loads less than 1,000 copies/mL. One as yet unpublished study of more than 1,200 woman-infant pairs determined the transmission rate to be 9.8% among women with low viral loads who don't get antiretroviral therapy, compared with 1.0% for women who do, yielding a highly significant odds ratio of 0.10.

Finally, there's the question of what one should do for women who are unlikely to comply with an antiretroviral regimen because of their life circumstances. Another unpublished study looked at the cost-effectiveness of directly observed therapy, which requires keeping women in the hospital during the third trimester. This resulted in a greatly reduced transmission rate and a cost saving of \$3,200 per pregnancy.

Dr. Cohan routinely orders directly observed therapy for women in difficult circumstances. “It drives the nurses crazy and the patients often go kind of stir crazy, but we've had remarkable success at keeping these women in the hospital and getting their virus suppressed,” Dr. Cohan said.

BONIVA® (ibandronate sodium) INJECTION

BRIEF SUMMARY
CONSULT PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION

CONTRAINDICATIONS

- Known hypersensitivity to BONIVA Injection or to any of its excipients
- Uncorrected hypocalcemia (see **PRECAUTIONS: General**)

WARNINGS

BONIVA Injection, like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values (see **PRECAUTIONS**). BONIVA Injection must only be administered intravenously. Care must be taken not to administer BONIVA Injection intra-arterially or paravenously as this could lead to tissue damage. Do not administer BONIVA Injection by any other route of administration. The safety and efficacy of BONIVA Injection following non-intravenous routes of administration have not been established.

PRECAUTIONS: General

Mineral Metabolism: Hypocalcemia, hypovitaminosis D, and other disturbances of bone and mineral metabolism must be effectively treated before starting BONIVA Injection therapy. Adequate intake of calcium and vitamin D is important in all patients. Patients must receive supplemental calcium and vitamin D.

Renal Impairment: Treatment with intravenous bisphosphonates has been associated with renal toxicity manifested as deterioration in renal function (ie, increased serum creatinine) and in rare cases, acute renal failure. No cases of acute renal failure were observed in controlled clinical trials in which intravenous BONIVA was administered as a 15- to 30-second bolus. The risk of serious renal toxicity with other intravenous bisphosphonates appears to be inversely related to the rate of drug administration. Patients who receive BONIVA Injection should have serum creatinine measured prior to each dosage administration. Patients with concomitant diseases that have the potential for adverse effects on the kidney or patients who are taking concomitant medications that have the potential for adverse effects on the kidney should be assessed, as clinically appropriate. Treatment should be withheld for renal deterioration. BONIVA Injection should not be administered to patients with severe renal impairment (ie, patients with serum creatinine >200 µmol/L [2.3 mg/dL] or creatinine clearance [measured or estimated] <30 mL/min).

Jaw Osteonecrosis: Osteonecrosis, primarily in the jaw, has been reported in patients treated with bisphosphonates. Most cases have been in cancer patients undergoing dental procedures, but some have occurred in patients with postmenopausal osteoporosis or other diagnoses. Known risk factors for osteonecrosis include a diagnosis of cancer, concomitant therapies (eg, chemotherapy, radiotherapy, corticosteroids), and co-morbid disorders (eg, anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases have been in patients treated with bisphosphonates intravenously but some have been in patients treated orally. For patients who develop osteonecrosis of the jaw (ONJ) while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.

Musculoskeletal Pain: In postmarketing experience, severe and occasionally incapacitating bone, joint and/or muscle pain has been reported in patients taking bisphosphonates that are approved for the prevention and treatment of osteoporosis (see **ADVERSE REACTIONS**). However, such reports have been infrequent. This category of drugs includes BONIVA (ibandronate sodium) Injection. Most of the patients were postmenopausal women. The time to onset of symptoms varied from one day to several months after starting the drug. Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate.

Information for Patients: BONIVA Injection must be administered intravenously only by a health care professional. Patients should be instructed to read the Patient Information Leaflet carefully before BONIVA Injection is administered and to re-read it each time the prescription is renewed. BONIVA Injection should be administered once every 3 months. If the dose is missed, the injection should be administered as soon as it can be rescheduled. Thereafter, injections should be scheduled every 3 months from the date of the last injection. Do not administer BONIVA Injection more frequently than once every 3 months. Patients must receive supplemental calcium and vitamin D.

Drug Interactions

See **FULL PRESCRIBING INFORMATION, CLINICAL PHARMACOLOGY: Drug Interactions**

Drug/Laboratory Test Interactions: Bisphosphonates are known to interfere with the use of bone-imaging agents. Specific studies with ibandronate have not been performed.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Carcinogenesis: In a 104-week carcinogenicity study, doses of 3, 7, or 15 mg/kg/day were administered by oral gavage to Wistar rats (systemic exposures in males and females up to 3 and 1 times, respectively, human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). There were no significant drug-related tumor findings in male or female rats. In a 78-week carcinogenicity study, doses of 5, 20, or 40 mg/kg/day were administered by oral gavage to NMRI mice (exposures in males and females up to 96 and 14 times, respectively, human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). There were no significant drug-related tumor findings in male or female mice. In a 90-week carcinogenicity study, doses of 5, 20, or 80 mg/kg/day were administered in the drinking water to NMRI mice. A dose-related increased incidence of adrenal subcapsular adenoma/carcinoma was observed in female mice, which was statistically significant at 80 mg/kg/day (32 to 51 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). The relevance of these findings to humans is unknown.

Mutagenesis: There was no evidence for a mutagenic or clastogenic potential of ibandronate in the following assays: *in vitro* bacterial mutagenesis assay in *Salmonella typhimurium* and *Escherichia coli* (Ames test), mammalian cell mutagenesis assay in Chinese hamster V79 cells, and chromosomal aberration test in human peripheral lymphocytes, each with and without metabolic activation. Ibandronate was not genotoxic in the *in vivo* mouse micronucleus tests for chromosomal damage.

Impairment of Fertility: In female rats treated from 14 days prior to mating through gestation, decreases in fertility, corpora lutea and implantation sites, and increased preimplantation loss were observed at an intravenous dose of 1.2 mg/kg/day (117 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). In male rats treated for 28 days prior to mating, a decrease in sperm production and altered sperm morphology were observed at intravenous doses of 0.3 mg/kg/day (≥40 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison).

Pregnancy: Pregnancy Category C. In pregnant rats given intravenous doses of 0.05, 0.15, or 0.5 mg/kg/day from Day 17 post-coitum until Day 20 postpartum, ibandronate treatment resulted in dystocia, maternal mortality, and early postnatal pup loss in all dose groups (≥2 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison).

Reduced body weight at birth was observed at 0.15 and 0.5 mg/kg/day (≥4 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). Pups exhibited abnormal odontology that decreased food consumption and body weight gain at 0.15 and 0.5 mg/kg/day (≥18 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). Periparturient mortality has also been observed with other bisphosphonates and appears to be a class effect related to inhibition of skeletal calcium mobilization resulting in hypocalcemia and dystocia. Exposure of pregnant rats during the period of organogenesis resulted in an increased fetal incidence of RPU (renal pelvis ureter) syndrome at an intravenous dose of 1 mg/kg/day (≥47 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). In this spontaneous delivery study, dystocia was counteracted by perinatal calcium supplementation. In rat studies with intravenous dosing during gestation, fetal weight and pup growth were reduced at doses ≥0.1 mg/kg/day (≥5 times human exposure at the recommended intravenous dose of 3 mg every 3 months, based on cumulative AUC comparison). In pregnant rabbits given intravenous doses of 0.03, 0.07 or 0.2 mg/kg/day during the period of organogenesis, maternal mortality, reduced maternal body weight gain, decreased litter size due to increased resorption rate, and decreased fetal weight were observed at 0.2 mg/kg/day (19 times the recommended human intravenous dose of 3 mg every 3 months, based on cumulative body surface area comparison, mg/m²). Bisphosphonates are incorporated into the bone matrix, from where they are gradually released over periods of weeks to years. The extent of bisphosphonate incorporation into adult bone, and hence, the amount available for release back into the systemic circulation, is directly related to the total dose and duration of bisphosphonate use. Although there are no data on fetal risk in humans, bisphosphonates do cause fetal harm in animals, and animal data suggest that uptake of bisphosphonates into fetal bone is greater than into maternal bone. Therefore, there is a theoretical risk of fetal harm (eg, skeletal and other abnormalities) if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on this risk has not been established. There are no adequate and well-controlled studies in pregnant women. BONIVA Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.

Nursing Mothers: In lactating rats treated with intravenous doses of 0.08 mg/kg, ibandronate was present in breast milk at concentrations of 8.1 to 0.4 ng/mL from 2 to 24 hours after dose administration. Concentrations in milk averaged 1.5 times plasma concentrations. It is not known whether BONIVA is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BONIVA Injection is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Of the patients receiving BONIVA Injection 3 mg every 3 months for 1 year (DIVA study), 51% were over 65 years of age. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity in some older individuals cannot be ruled out.

ADVERSE REACTIONS

Daily Oral Tablet: Treatment with BONIVA 2.5 mg daily oral tablet was studied, in over 3900 patients in postmenopausal osteoporosis trials of up to 3 years duration. The overall adverse event profile of BONIVA 2.5 mg once daily tablet in these studies was similar to that of placebo.

Most adverse events were mild or moderate and did not lead to discontinuation. The incidence of serious adverse events was 20% in the placebo group and 23% in the BONIVA 2.5 mg daily oral tablet group. The percentage of patients who withdrew from treatment due to adverse events was approximately 17% in both the BONIVA 2.5 mg daily oral tablet group and the placebo group. Overall, and according to body system, there was no difference between BONIVA daily oral tablet and placebo, with adverse events of the digestive system being the most common reason for withdrawal.

Table 1 lists adverse events from the Treatment and Prevention Studies reported in ≥2% of patients and in more patients treated with BONIVA 2.5 mg daily oral tablet than patients treated with placebo. Adverse events are shown without attribution of causality.

Table 2 lists adverse events reported in >2% of patients without attribution of causality.

Table 2: Adverse Events With an Incidence of at Least 2% in Patients Treated with BONIVA Injection (3 mg once every 3 months) or BONIVA Daily Oral Tablet (2.5 mg)

Body System/Adverse Event	BONIVA	
	2.5 mg Daily (Oral) % (n=465)	3 mg q 3 mo (IV) % (n=469)
Infections and Infestations		
Influenza	8.0	4.7
Nasopharyngitis	6.0	3.4
Cystitis	3.4	1.9
Gastroenteritis	3.4	1.5
Urinary Tract Infection	3.2	2.6
Bronchitis	2.8	2.1
Upper Respiratory Tract Infection	2.8	1.1
Gastrointestinal Disorders		
Abdominal Pain*	5.6	5.1
Dyspepsia	4.3	3.6
Nausea	4.3	2.1
Constipation	4.1	3.4
Diarrhea	2.4	2.8
Gastritis	2.2	1.9
Musculoskeletal and Connective Tissue Disorders		
Arthralgia	8.6	9.6
Back Pain	7.5	7.0
Localized Osteoarthritis	2.4	1.5
Pain in Extremity	2.2	2.8
Myalgia	0.9	2.8
Nervous System Disorders		
Dizziness	2.8	1.9
Headache	2.6	3.6
Vascular Disorders		
Hypertension	7.1	5.3
Psychiatric Disorders		
Insomnia	2.6	1.1
Depression	2.2	1.3
General Disorders and Administration Site Conditions		
Influenza-like illness†	1.1	4.9
Fatigue	1.1	2.8
Skin and Subcutaneous Tissue Disorders		
Rash‡	2.8	2.3
Metabolism and Nutrition		
Hypercholesterolemia	4.3	1.5

*Is a combination of abdominal pain and abdominal pain upper.

†Combination of influenza-like illness and acute phase reaction.

‡Combination of rash, rash pruritic, rash macular, dermatitis, dermatitis allergic, exanthem, erythema, rash papular, rash generalized, dermatitis medicamentosa, rash erythematous.

Acute Phase Reaction-like Events: Symptoms consistent with acute phase reaction (APR) have been reported with intravenous bisphosphonate use. The overall incidence of patients with APR-like events was higher in the intravenous treatment group (4% in the BONIVA 2.5 mg daily oral tablet group vs. 10% in the BONIVA Injection 3 mg every 3 months group). These incidence rates are based on reporting of any of 33 potential APR-like symptoms within 3 days of an IV dose and for a duration of 7 days or less. In most cases, no specific treatment was required and the symptoms subsided within 24 to 48 hours.

Injection Site Reactions: Local reactions at the injection site, such as redness or swelling, were observed infrequently, but at a higher incidence in patients treated with BONIVA Injection 3 mg every 3 months (<2%; 8/469) than in patients treated with placebo injections (<1%; 1/465). In most cases, the reaction was of mild to moderate severity.

Ocular Adverse Events: Bisphosphonates may be associated with ocular inflammation such as uveitis and scleritis. In some cases, these events did not resolve until the bisphosphonate was discontinued.

Laboratory Test Findings: There were no clinically significant changes from baseline values or shifts in any laboratory variable with oral ibandronate. As expected with bisphosphonate treatment, a decrease in total alkaline phosphatase levels was seen with 2.5 mg daily oral ibandronate compared to placebo. There was no difference compared with placebo for laboratory abnormalities indicative of hepatic or renal dysfunction, hypocalcemia, or hypophosphatemia. There also was no evidence that BONIVA Injection 3 mg every 3 months induced clinically significant laboratory abnormalities indicative of hepatic or renal dysfunction compared to BONIVA 2.5 mg daily oral tablet.

OVERDOSAGE: No cases of overdose were reported in premarketing studies with BONIVA Injection. Intravenous overdose may result in hypocalcemia, hypophosphatemia, and hypomagnesemia. Clinically relevant reductions in serum levels of calcium, phosphorus, and magnesium should be corrected by intravenous administration of calcium gluconate, potassium or sodium phosphate, and magnesium sulfate, respectively. Dialysis would not be beneficial unless it is administered within 2 hours following the overdose.

Distributed by: Co-promoted by Roche Laboratories Inc. and

	Pharmaceuticals		GlaxoSmithKline
Roche Laboratories Inc. 340 Kingsland Street Nutley, New Jersey 07110-1199 www.rocheusa.com		GlaxoSmithKline Research Triangle Park, NC 27709 www.gsk.com	

Issued: February 2006
Copyright © 2006 by Roche Laboratories Inc. All rights reserved.